Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Non Operating Income (2022 - 2026)

Ovid Therapeutics filings provide 5 years of Other Non Operating Income readings, the most recent being $858000.0 for Q1 2026.

  • Quarterly Other Non Operating Income fell 62.94% to $858000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.6 million through Mar 2026, down 26.44% year-over-year, with the annual reading at $25.0 million for FY2025, 29.41% down from the prior year.
  • Other Non Operating Income hit $858000.0 in Q1 2026 for Ovid Therapeutics, down from $22.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $29.0 million in Q2 2024 and bottomed at -$780000.0 in Q3 2024.
  • Average Other Non Operating Income over 5 years is $4.1 million, with a median of $858000.0 recorded in 2026.
  • Peak annual rise in Other Non Operating Income hit 1546.15% in 2024, while the deepest fall reached 200.52% in 2024.
  • Ovid Therapeutics' Other Non Operating Income stood at $668123.0 in 2022, then skyrocketed by 329.11% to $2.9 million in 2023, then plummeted by 48.76% to $1.5 million in 2024, then skyrocketed by 1394.69% to $22.0 million in 2025, then tumbled by 96.09% to $858000.0 in 2026.
  • Per Business Quant, the three most recent readings for OVID's Other Non Operating Income are $858000.0 (Q1 2026), $22.0 million (Q4 2025), and $365000.0 (Q3 2025).